Friday, April 18, 2014

This is what "ethics" at the FDA looks like

Remember the prenatal dex controversy, and the ugly role played by the American Journal of Bioethics?  It just got worse.  Read about it on the Impact Ethics blog.

1 comment:

  1. Stunning as this is, why is this any different than that of the University of Minnesota’s psychiatry professor Charles Schulz claim that AstraZeneca’s Seroquel performance was superior to older drugs like Haldol when in fact the research data he was working with showed Haldol to be more efficacious. Schulz made this claim in 2000. From 2002 to 2007, he received $112,000 in fees from AstraZeneca, plus about $450,000 from Eli Lilly, he then went ahead and sat on the DSM advisory board and offered his prostituted opinion.